Age-Dependent Evaluation of Immunoglobulin G Response after Chikungunya Virus Infection

Patil, Harshad P.; Gosavi, Mrunal; Mishra, Akhilesh C.; Arankalle, Vidya A.

doi:10.4269/ajtmh.20-1398

Cited by 6 publications

(3 citation statements)

References 23 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar trend was observed among age groups in studies conducted in India, Singapore, and Nigeria [ 52 , 56 , 58 ]. The relationship between increasing age and CHIKV susceptibility has been attributed to the increased degree of exposure and impaired immune function in the elderly population [ 58 , 59 ]. However, the seroprevalence of anti-CHIKV IgM antibodies was highest among children ≤ 5 years old and adults ≥ 46 years old, which is indicative of acute infection in the population.…”

Section: Discussionmentioning

confidence: 99%

Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018

et al. 2021

View full text Add to dashboard Cite

Introduction Chikungunya virus (CHIKV) is a mosquito-borne virus known to cause acute febrile illness associated with debilitating polyarthritis. In 2019, several institutions in Myanmar reported a CHIKV outbreak. There are no official reports of CHIKV cases between 2011 and 2018. Therefore, this study sought to determine the seroprevalence of CHIKV infection before the 2019 outbreak. Methods A total of 1,544 serum samples were collected from healthy volunteers and patients with febrile illnesses in Yangon, Mandalay, and the Myeik district in 2013, 2015, and 2018. Participants ranged from one month to 65 years of age. Antibody screening was performed with in-house anti-CHIKV IgG and IgM ELISA. A neutralization assay was used as a confirmatory test. Results The seroprevalence of anti-CHIKV IgM and anti-CHIKV IgG was 8.9% and 28.6%, respectively, with an overall seropositivity rate of 34.5%. A focus reduction neutralization assay confirmed 32.5% seroprevalence of CHIKV in the study population. Age, health status, and region were significantly associated with neutralizing antibodies (NAbs) and CHIKV seropositivity (p < 0.05), while gender was not (p = 0.9). Seroprevalence in 2013, 2015, and 2018 was 32.1%, 28.8%, and 37.3%, respectively. Of the clinical symptoms observed in participants with fevers, arthralgia was mainly noted in CHIKV-seropositive patients. Conclusion The findings in this study reveal the circulation of CHIKV in Myanmar’s Mandalay, Yangon, and Myeik regions before the 2019 CHIKV outbreak. As no treatment or vaccine for CHIKV exists, the virus must be monitored through systematic surveillance in Myanmar.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The importance of antibodies that serve as a critical barrier against viral infection was also demonstrated for CHIKV (19).…”

Section: Discussionmentioning

confidence: 97%

Seroprevalence and clinical manifestations of Chikungunya infection in Makassar city, Indonesia

Emelia Abdullah

2024

Gac Méd Caracas

View full text Add to dashboard Cite

Background: Chikungunya is a vector-borne disease with a high morbidity rate, spread in dengue hemorrhagic fever endemic areas because the vector carrying the virus is transmitted by the same mosquitoes, namely Aedes Aegypti and Aedes Albopictus. The number of mosquito breeding sites is often associated with an increased incidence of chikungunya disease. The proximity of mosquito breeding sites to human habitation is a significant risk factor for chikungunya. Data related to chikungunya is still lacking in Makassar. This study aims to understand the prevalence of CHIKV infection through serodiagnosis by measuring CHIKV IgG antibodies and looking at the history of clinical symptoms associated with CHIKV infection in Makassar to reduce widespread transmission.

show abstract

“…Arankalle’s group aimed to evaluate envelope-specific immune responses in individuals with CHIKV infection in 2006. The findings demonstrated that lower levels of IFN-γ may be associated with the severity of the disease in these individuals, and T cell epitopes recognized on the envelope region of CHIKV by all patients [ 208 , 209 ]. This team intended to create potential vaccines using either recombinant CHIKV-E2 protein or chemically inactivated whole CHIKV.…”

Section: Chikv Research: Indian Scenariomentioning

confidence: 99%

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

et al. 2023

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an infectious agent spread by mosquitos, that has engendered endemic or epidemic outbreaks of Chikungunya fever (CHIKF) in Africa, South-East Asia, America, and a few European countries. Like most tropical infections, CHIKV is frequently misdiagnosed, underreported, and underestimated; it primarily affects areas with limited resources, like developing nations. Due to its high transmission rate and lack of a preventive vaccine or effective treatments, this virus poses a serious threat to humanity. After a 32-year hiatus, CHIKV reemerged as the most significant epidemic ever reported, in India in 2006. Since then, CHIKV-related research was begun in India, and up to now, more than 800 peer-reviewed research papers have been published by Indian researchers and medical practitioners. This review gives an overview of the outbreak history and CHIKV-related research in India, to favor novel high-quality research works intending to promote effective treatment and preventive strategies, including vaccine development, against CHIKV infection.

show abstract

Age-Dependent Evaluation of Immunoglobulin G Response after Chikungunya Virus Infection

Cited by 6 publications

References 23 publications

Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018

Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018

Seroprevalence and clinical manifestations of Chikungunya infection in Makassar city, Indonesia

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

Contact Info

Product

Resources

About